['rheumatoid arthritis']
['methotrexate', 'upadacitinib', 'placebo upadacitinib', 'placebo methotrexate']

        Inclusion Criteria:

          -  Diagnosis of RA for >= 3 months.

          -  Subjects must have been on oral or parenteral MTX therapy >= 3 months and on a stable
             dose for >= 4 weeks prior to first dose of study drug.

          -  Must have discontinued all conventional synthetic disease-modifying anti-rheumatic
             drugs (csDMARDs) (other than MTX) >= 4 weeks prior to first dose of study drug.

          -  Meets the following minimum disease activity criteria: >= 6 swollen joints (based on
             66 joint counts) and >= 6 tender joints (based on 68 joint counts) at Screening and
             Baseline Visits.

        Exclusion Criteria:

          -  Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to
             tofacitinib, baricitinib, and filgotinib).

          -  Prior exposure to any biological disease-modifying anti-rheumatic drugs (bDMARDs).

          -  Current diagnosis of inflammatory joint disease other than RA. Current diagnosis of
             secondary Sjogren's Syndrome is permitted.
      